Navigation Links
Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010

MIAMI BEACH, Fla., Aug. 23, 2011 /PRNewswire/ -- Biotechnology leader Divine Skin Inc. (DSKX) posted its highest quarterly revenue, $2.33 million, in the second quarter. The expanding innovator of personal care solutions credits recent investments in production for clearing backorders and accelerating sales, which are 79 percent ahead of the same period in 2010.

"One of our challenges has been keeping up with demand," said Divine Skin CEO Daniel Khesin. "We have invested significant resources into setting up a more robust operations platform. Now we have the right people in the right jobs managing the right plans for procurement, manufacturing, and accounting infrastructure. We will therefore continue to scale up to much more impressive numbers."

The results come after a busy four months of announcements:

  • Naming of cosmetics veteran Robin Powell, respected for his success at Sebastian and TIGI, as president.
  • Explosive growth in salon distribution, including new channels totaling thousands of additional doors both domestically and abroad.  
  • Plans for an oral analgesic to compete with Tylenol, Advil, and aspirin.
  • Expansion into advanced nutritional supplements with NutraOrigin.
  • Agreement for India's largest pharmaceutical company to sell DS Laboratories treatments.

Divine Skin maintains a core focus on biotechnology development while building its consumer goods business. It's ongoing clinical studies for topical therapies have helped identify new molecules and many proprietary technologies in the treatment of common skin conditions such as alopecia. Recently the company has announced the launch of Nanoxidil, a new material to designed to surpass the efficacy of minoxidil. This kind of innovations within personal care is expected to maintain Divine Skin's position as a category leader in niche categories and drive strong revenue growth.

"At the heart of this business is the relentless drive for innovation of personal care products," commented Khesin. "Every day we are only getting better at what we do and creativity is reaching new horizons. Customers and shareholders should prepare for very exciting things to come," he added.

About Divine Skin

Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.

DS Laboratories, its flagship brand, offers high-performance topical solutions to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, improve hygiene, and reduce cellulite and wrinkles. Bioavailability is enhanced through encapsulation (

The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging (

Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (

The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers (

NutraOrigin blends nutritional supplements that address the health concerns expressed by consumers, including fatigue, headache, obesity, mobility, menopause, erectile dysfunction, and others. In clinical trials for the US government, its Omega line proved to enhance mental function (

Abner Silva
Investor Relations
Divine Skin Inc.

SOURCE Divine Skin Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biotech Developer Divine Skin (DSKX) Debuts New Hair-Growth Molecule Nanoxidil
2. Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX)
3. First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin
4. Divine Skin Announces Four Deals for Explosive Distribution Growth
5. Divine Skin Posts Record Sales for 2010: Up 55% Over 2009
6. Fiberstar Posts Strong Second Quarter Operating Results on Continued Rising International Demand
7. Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear
8. Switzerland Posts Biotech Gains in 2009
9. OpenQ Posts a 200% Revenue Growth in the First Half of 2009
10. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
11. Synvista Therapeutics Posts Letter to Stockholders on Web Site
Post Your Comments:
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... 2016 adds 2016 ... its pharmaceuticals section with historic and forecast data ... more. Complete report on the Cell ... 15 companies and supported with 261 tables and ... . The Global Cell Culture Media ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):